XML 66 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2013
Revenue Accounted for 10% or More of Total Revenues

Customers whose collaborative research and development revenue accounted for 10% or more of total revenues were as follows:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2013

 

 

 

2012

 

 

 

2013

 

 

 

2012

 

Novartis AG             

 

—

 

 

 

  100

%

 

 

—

 

 

 

  100

%

Bristol-Myers Squibb Company and Pfizer Inc.             

 

  28

%

 

 

—

 

 

 

  46

%

 

 

—

 

Bayer Pharma, AG and Janssen Pharmaceuticals, Inc.             

 

  37

%

 

 

—

 

 

 

  41

%

 

 

—

 

Daiichi Sankyo, Inc.              

 

  32

%

 

 

—

 

 

 

  12

%

 

 

—